First Time Loading...
G

Glenmark Life Sciences Ltd
NSE:GLS

Watchlist Manager
Glenmark Life Sciences Ltd
NSE:GLS
Watchlist
Price: 805.7 INR -1.14% Market Closed
Updated: Apr 29, 2024

Glenmark Life Sciences Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Glenmark Life Sciences Ltd
Net Income (Common) Peer Comparison

Comparables:
DRREDDY
CIPLA
SUNPHARMA
ZYDUSLIFE
M
MANKIND

Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Life Sciences Ltd
NSE:GLS
Net Income (Common)
₹4.7B
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Net Income (Common)
₹52.3B
CAGR 3-Years
34%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Net Income (Common)
₹37.1B
CAGR 3-Years
18%
CAGR 5-Years
23%
CAGR 10-Years
10%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Net Income (Common)
₹89.1B
CAGR 3-Years
55%
CAGR 5-Years
21%
CAGR 10-Years
13%
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
Net Income (Common)
₹29.7B
CAGR 3-Years
17%
CAGR 5-Years
8%
CAGR 10-Years
14%
M
Mankind Pharma Ltd
NSE:MANKIND
Net Income (Common)
₹12.8B
CAGR 3-Years
8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Glenmark Life Sciences Ltd's Net Income (Common)?
Net Income (Common)
4.7B INR

Based on the financial report for Mar 31, 2023, Glenmark Life Sciences Ltd's Net Income (Common) amounts to 4.7B INR.

What is Glenmark Life Sciences Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
14%

Over the last year, the Net Income (Common) growth was 12%. The average annual Net Income (Common) growth rates for Glenmark Life Sciences Ltd have been 14% over the past three years .